Global Acute Myeloid Leukemia (AML) Therapeutics Market Research Report 2023

Report ID: 1899075 | Published Date: Jan 2025 | No. of Page: 85 | Base Year: 2024 | Rating: 4.5 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Acute Myeloid Leukemia (AML) Therapeutics Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
        1.2.2 Chemotherapy
        1.2.3 Radiation therapy
        1.2.4 Stem Cell Transplant
        1.2.5 Targeted Therapy
        1.2.6 Others
    1.3 Market by Application
        1.3.1 Global Acute Myeloid Leukemia (AML) Therapeutics Market Share by Application: 2017 VS 2021 VS 2028
        1.3.2 Hospital
        1.3.3 Clinics
        1.3.4 Others
    1.4 Study Objectives
    1.5 Years Considered
2 Global Growth Trends
    2.1 Global Acute Myeloid Leukemia (AML) Therapeutics Market Perspective (2017-2028)
    2.2 Acute Myeloid Leukemia (AML) Therapeutics Growth Trends by Region
        2.2.1 Acute Myeloid Leukemia (AML) Therapeutics Market Size by Region: 2017 VS 2021 VS 2028
        2.2.2 Acute Myeloid Leukemia (AML) Therapeutics Historic Market Size by Region (2017-2022)
        2.2.3 Acute Myeloid Leukemia (AML) Therapeutics Forecasted Market Size by Region (2023-2028)
    2.3 Acute Myeloid Leukemia (AML) Therapeutics Market Dynamics
        2.3.1 Acute Myeloid Leukemia (AML) Therapeutics Industry Trends
        2.3.2 Acute Myeloid Leukemia (AML) Therapeutics Market Drivers
        2.3.3 Acute Myeloid Leukemia (AML) Therapeutics Market Challenges
        2.3.4 Acute Myeloid Leukemia (AML) Therapeutics Market Restraints
3 Competition Landscape by Key Players
    3.1 Global Top Acute Myeloid Leukemia (AML) Therapeutics Players by Revenue
        3.1.1 Global Top Acute Myeloid Leukemia (AML) Therapeutics Players by Revenue (2017-2022)
        3.1.2 Global Acute Myeloid Leukemia (AML) Therapeutics Revenue Market Share by Players (2017-2022)
    3.2 Global Acute Myeloid Leukemia (AML) Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Players Covered: Ranking by Acute Myeloid Leukemia (AML) Therapeutics Revenue
    3.4 Global Acute Myeloid Leukemia (AML) Therapeutics Market Concentration Ratio
        3.4.1 Global Acute Myeloid Leukemia (AML) Therapeutics Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Acute Myeloid Leukemia (AML) Therapeutics Revenue in 2021
    3.5 Acute Myeloid Leukemia (AML) Therapeutics Key Players Head office and Area Served
    3.6 Key Players Acute Myeloid Leukemia (AML) Therapeutics Product Solution and Service
    3.7 Date of Enter into Acute Myeloid Leukemia (AML) Therapeutics Market
    3.8 Mergers & Acquisitions, Expansion Plans
4 Acute Myeloid Leukemia (AML) Therapeutics Breakdown Data by Type
    4.1 Global Acute Myeloid Leukemia (AML) Therapeutics Historic Market Size by Type (2017-2022)
    4.2 Global Acute Myeloid Leukemia (AML) Therapeutics Forecasted Market Size by Type (2023-2028)
5 Acute Myeloid Leukemia (AML) Therapeutics Breakdown Data by Application
    5.1 Global Acute Myeloid Leukemia (AML) Therapeutics Historic Market Size by Application (2017-2022)
    5.2 Global Acute Myeloid Leukemia (AML) Therapeutics Forecasted Market Size by Application (2023-2028)
6 North America
    6.1 North America Acute Myeloid Leukemia (AML) Therapeutics Market Size (2017-2028)
    6.2 North America Acute Myeloid Leukemia (AML) Therapeutics Market Size by Country (2017-2022)
    6.3 North America Acute Myeloid Leukemia (AML) Therapeutics Market Size by Country (2023-2028)
    6.4 United States
    6.5 Canada
7 Europe
    7.1 Europe Acute Myeloid Leukemia (AML) Therapeutics Market Size (2017-2028)
    7.2 Europe Acute Myeloid Leukemia (AML) Therapeutics Market Size by Country (2017-2022)
    7.3 Europe Acute Myeloid Leukemia (AML) Therapeutics Market Size by Country (2023-2028)
    7.4 Germany
    7.5 France
    7.6 U.K.
    7.7 Italy
    7.8 Russia
    7.9 Nordic Countries
8 Asia-Pacific
    8.1 Asia-Pacific Acute Myeloid Leukemia (AML) Therapeutics Market Size (2017-2028)
    8.2 Asia-Pacific Acute Myeloid Leukemia (AML) Therapeutics Market Size by Country (2017-2022)
    8.3 Asia-Pacific Acute Myeloid Leukemia (AML) Therapeutics Market Size by Country (2023-2028)
    8.4 China
    8.5 Japan
    8.6 South Korea
    8.7 Southeast Asia
    8.8 India
    8.9 Australia
9 Latin America
    9.1 Latin America Acute Myeloid Leukemia (AML) Therapeutics Market Size (2017-2028)
    9.2 Latin America Acute Myeloid Leukemia (AML) Therapeutics Market Size by Country (2017-2022)
    9.3 Latin America Acute Myeloid Leukemia (AML) Therapeutics Market Size by Country (2023-2028)
    9.4 Mexico
    9.5 Brazil
10 Middle East & Africa
    10.1 Middle East & Africa Acute Myeloid Leukemia (AML) Therapeutics Market Size (2017-2028)
    10.2 Middle East & Africa Acute Myeloid Leukemia (AML) Therapeutics Market Size by Country (2017-2022)
    10.3 Middle East & Africa Acute Myeloid Leukemia (AML) Therapeutics Market Size by Country (2023-2028)
    10.4 Turkey
    10.5 Saudi Arabia
    10.6 UAE
11 Key Players Profiles
    11.1 Bristol-Myers Squibb
        11.1.1 Bristol-Myers Squibb Company Detail
        11.1.2 Bristol-Myers Squibb Business Overview
        11.1.3 Bristol-Myers Squibb Acute Myeloid Leukemia (AML) Therapeutics Introduction
        11.1.4 Bristol-Myers Squibb Revenue in Acute Myeloid Leukemia (AML) Therapeutics Business (2017-2022)
        11.1.5 Bristol-Myers Squibb Recent Development
    11.2 Novartis
        11.2.1 Novartis Company Detail
        11.2.2 Novartis Business Overview
        11.2.3 Novartis Acute Myeloid Leukemia (AML) Therapeutics Introduction
        11.2.4 Novartis Revenue in Acute Myeloid Leukemia (AML) Therapeutics Business (2017-2022)
        11.2.5 Novartis Recent Development
    11.3 Roche
        11.3.1 Roche Company Detail
        11.3.2 Roche Business Overview
        11.3.3 Roche Acute Myeloid Leukemia (AML) Therapeutics Introduction
        11.3.4 Roche Revenue in Acute Myeloid Leukemia (AML) Therapeutics Business (2017-2022)
        11.3.5 Roche Recent Development
    11.4 Genmab
        11.4.1 Genmab Company Detail
        11.4.2 Genmab Business Overview
        11.4.3 Genmab Acute Myeloid Leukemia (AML) Therapeutics Introduction
        11.4.4 Genmab Revenue in Acute Myeloid Leukemia (AML) Therapeutics Business (2017-2022)
        11.4.5 Genmab Recent Development
    11.5 GlaxoSmithKline Pharmaceuticals
        11.5.1 GlaxoSmithKline Pharmaceuticals Company Detail
        11.5.2 GlaxoSmithKline Pharmaceuticals Business Overview
        11.5.3 GlaxoSmithKline Pharmaceuticals Acute Myeloid Leukemia (AML) Therapeutics Introduction
        11.5.4 GlaxoSmithKline Pharmaceuticals Revenue in Acute Myeloid Leukemia (AML) Therapeutics Business (2017-2022)
        11.5.5 GlaxoSmithKline Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer
    13.3 Author Details

List of Tables
    Table 1. Global Acute Myeloid Leukemia (AML) Therapeutics Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
    Table 2. Key Players of Chemotherapy
    Table 3. Key Players of Radiation therapy
    Table 4. Key Players of Stem Cell Transplant
    Table 5. Key Players of Targeted Therapy
    Table 6. Key Players of Others
    Table 7. Global Acute Myeloid Leukemia (AML) Therapeutics Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
    Table 8. Global Acute Myeloid Leukemia (AML) Therapeutics Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
    Table 9. Global Acute Myeloid Leukemia (AML) Therapeutics Market Size by Region (2017-2022) & (US$ Million)
    Table 10. Global Acute Myeloid Leukemia (AML) Therapeutics Market Share by Region (2017-2022)
    Table 11. Global Acute Myeloid Leukemia (AML) Therapeutics Forecasted Market Size by Region (2023-2028) & (US$ Million)
    Table 12. Global Acute Myeloid Leukemia (AML) Therapeutics Market Share by Region (2023-2028)
    Table 13. Acute Myeloid Leukemia (AML) Therapeutics Market Trends
    Table 14. Acute Myeloid Leukemia (AML) Therapeutics Market Drivers
    Table 15. Acute Myeloid Leukemia (AML) Therapeutics Market Challenges
    Table 16. Acute Myeloid Leukemia (AML) Therapeutics Market Restraints
    Table 17. Global Acute Myeloid Leukemia (AML) Therapeutics Revenue by Players (2017-2022) & (US$ Million)
    Table 18. Global Acute Myeloid Leukemia (AML) Therapeutics Market Share by Players (2017-2022)
    Table 19. Global Top Acute Myeloid Leukemia (AML) Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Acute Myeloid Leukemia (AML) Therapeutics as of 2021)
    Table 20. Ranking of Global Top Acute Myeloid Leukemia (AML) Therapeutics Companies by Revenue (US$ Million) in 2021
    Table 21. Global 5 Largest Players Market Share by Acute Myeloid Leukemia (AML) Therapeutics Revenue (CR5 and HHI) & (2017-2022)
    Table 22. Key Players Headquarters and Area Served
    Table 23. Key Players Acute Myeloid Leukemia (AML) Therapeutics Product Solution and Service
    Table 24. Date of Enter into Acute Myeloid Leukemia (AML) Therapeutics Market
    Table 25. Mergers & Acquisitions, Expansion Plans
    Table 26. Global Acute Myeloid Leukemia (AML) Therapeutics Market Size by Type (2017-2022) & (US$ Million)
    Table 27. Global Acute Myeloid Leukemia (AML) Therapeutics Revenue Market Share by Type (2017-2022)
    Table 28. Global Acute Myeloid Leukemia (AML) Therapeutics Forecasted Market Size by Type (2023-2028) & (US$ Million)
    Table 29. Global Acute Myeloid Leukemia (AML) Therapeutics Revenue Market Share by Type (2023-2028)
    Table 30. Global Acute Myeloid Leukemia (AML) Therapeutics Market Size by Application (2017-2022) & (US$ Million)
    Table 31. Global Acute Myeloid Leukemia (AML) Therapeutics Revenue Market Share by Application (2017-2022)
    Table 32. Global Acute Myeloid Leukemia (AML) Therapeutics Forecasted Market Size by Application (2023-2028) & (US$ Million)
    Table 33. Global Acute Myeloid Leukemia (AML) Therapeutics Revenue Market Share by Application (2023-2028)
    Table 34. North America Acute Myeloid Leukemia (AML) Therapeutics Market Size by Country (2017-2022) & (US$ Million)
    Table 35. North America Acute Myeloid Leukemia (AML) Therapeutics Market Size by Country (2023-2028) & (US$ Million)
    Table 36. Europe Acute Myeloid Leukemia (AML) Therapeutics Market Size by Country (2017-2022) & (US$ Million)
    Table 37. Europe Acute Myeloid Leukemia (AML) Therapeutics Market Size by Country (2023-2028) & (US$ Million)
    Table 38. Asia-Pacific Acute Myeloid Leukemia (AML) Therapeutics Market Size by Region (2017-2022) & (US$ Million)
    Table 39. Asia-Pacific Acute Myeloid Leukemia (AML) Therapeutics Market Size by Region (2023-2028) & (US$ Million)
    Table 40. Latin America Acute Myeloid Leukemia (AML) Therapeutics Market Size by Country (2017-2022) & (US$ Million)
    Table 41. Latin America Acute Myeloid Leukemia (AML) Therapeutics Market Size by Country (2023-2028) & (US$ Million)
    Table 42. Middle East & Africa Acute Myeloid Leukemia (AML) Therapeutics Market Size by Country (2017-2022) & (US$ Million)
    Table 43. Middle East & Africa Acute Myeloid Leukemia (AML) Therapeutics Market Size by Country (2023-2028) & (US$ Million)
    Table 44. Bristol-Myers Squibb Company Detail
    Table 45. Bristol-Myers Squibb Business Overview
    Table 46. Bristol-Myers Squibb Acute Myeloid Leukemia (AML) Therapeutics Product
    Table 47. Bristol-Myers Squibb Revenue in Acute Myeloid Leukemia (AML) Therapeutics Business (2017-2022) & (US$ Million)
    Table 48. Bristol-Myers Squibb Recent Development
    Table 49. Novartis Company Detail
    Table 50. Novartis Business Overview
    Table 51. Novartis Acute Myeloid Leukemia (AML) Therapeutics Product
    Table 52. Novartis Revenue in Acute Myeloid Leukemia (AML) Therapeutics Business (2017-2022) & (US$ Million)
    Table 53. Novartis Recent Development
    Table 54. Roche Company Detail
    Table 55. Roche Business Overview
    Table 56. Roche Acute Myeloid Leukemia (AML) Therapeutics Product
    Table 57. Roche Revenue in Acute Myeloid Leukemia (AML) Therapeutics Business (2017-2022) & (US$ Million)
    Table 58. Roche Recent Development
    Table 59. Genmab Company Detail
    Table 60. Genmab Business Overview
    Table 61. Genmab Acute Myeloid Leukemia (AML) Therapeutics Product
    Table 62. Genmab Revenue in Acute Myeloid Leukemia (AML) Therapeutics Business (2017-2022) & (US$ Million)
    Table 63. Genmab Recent Development
    Table 64. GlaxoSmithKline Pharmaceuticals Company Detail
    Table 65. GlaxoSmithKline Pharmaceuticals Business Overview
    Table 66. GlaxoSmithKline Pharmaceuticals Acute Myeloid Leukemia (AML) Therapeutics Product
    Table 67. GlaxoSmithKline Pharmaceuticals Revenue in Acute Myeloid Leukemia (AML) Therapeutics Business (2017-2022) & (US$ Million)
    Table 68. GlaxoSmithKline Pharmaceuticals Recent Development
    Table 69. Research Programs/Design for This Report
    Table 70. Key Data Information from Secondary Sources
    Table 71. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Acute Myeloid Leukemia (AML) Therapeutics Market Share by Type: 2021 VS 2028
    Figure 2. Chemotherapy Features
    Figure 3. Radiation therapy Features
    Figure 4. Stem Cell Transplant Features
    Figure 5. Targeted Therapy Features
    Figure 6. Others Features
    Figure 7. Global Acute Myeloid Leukemia (AML) Therapeutics Market Share by Application in 2021 & 2028
    Figure 8. Hospital Case Studies
    Figure 9. Clinics Case Studies
    Figure 10. Others Case Studies
    Figure 11. Acute Myeloid Leukemia (AML) Therapeutics Report Years Considered
    Figure 12. Global Acute Myeloid Leukemia (AML) Therapeutics Market Size (US$ Million), Year-over-Year: 2017-2028
    Figure 13. Global Acute Myeloid Leukemia (AML) Therapeutics Market Size, (US$ Million), 2017 VS 2021 VS 2028
    Figure 14. Global Acute Myeloid Leukemia (AML) Therapeutics Market Share by Region: 2021 VS 2028
    Figure 15. Global Acute Myeloid Leukemia (AML) Therapeutics Market Share by Players in 2021
    Figure 16. Global Top Acute Myeloid Leukemia (AML) Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Acute Myeloid Leukemia (AML) Therapeutics as of 2021)
    Figure 17. The Top 10 and 5 Players Market Share by Acute Myeloid Leukemia (AML) Therapeutics Revenue in 2021
    Figure 18. North America Acute Myeloid Leukemia (AML) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 19. North America Acute Myeloid Leukemia (AML) Therapeutics Market Share by Country (2017-2028)
    Figure 20. United States Acute Myeloid Leukemia (AML) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 21. Canada Acute Myeloid Leukemia (AML) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 22. Europe Acute Myeloid Leukemia (AML) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 23. Europe Acute Myeloid Leukemia (AML) Therapeutics Market Share by Country (2017-2028)
    Figure 24. Germany Acute Myeloid Leukemia (AML) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 25. France Acute Myeloid Leukemia (AML) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 26. U.K. Acute Myeloid Leukemia (AML) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 27. Italy Acute Myeloid Leukemia (AML) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 28. Russia Acute Myeloid Leukemia (AML) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 29. Nordic Countries Acute Myeloid Leukemia (AML) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 30. Asia-Pacific Acute Myeloid Leukemia (AML) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 31. Asia-Pacific Acute Myeloid Leukemia (AML) Therapeutics Market Share by Region (2017-2028)
    Figure 32. China Acute Myeloid Leukemia (AML) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 33. Japan Acute Myeloid Leukemia (AML) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 34. South Korea Acute Myeloid Leukemia (AML) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 35. Southeast Asia Acute Myeloid Leukemia (AML) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 36. India Acute Myeloid Leukemia (AML) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 37. Australia Acute Myeloid Leukemia (AML) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 38. Latin America Acute Myeloid Leukemia (AML) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 39. Latin America Acute Myeloid Leukemia (AML) Therapeutics Market Share by Country (2017-2028)
    Figure 40. Mexico Acute Myeloid Leukemia (AML) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 41. Brazil Acute Myeloid Leukemia (AML) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 42. Middle East & Africa Acute Myeloid Leukemia (AML) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 43. Middle East & Africa Acute Myeloid Leukemia (AML) Therapeutics Market Share by Country (2017-2028)
    Figure 44. Turkey Acute Myeloid Leukemia (AML) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 45. Saudi Arabia Acute Myeloid Leukemia (AML) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 46. Bristol-Myers Squibb Revenue Growth Rate in Acute Myeloid Leukemia (AML) Therapeutics Business (2017-2022)
    Figure 47. Novartis Revenue Growth Rate in Acute Myeloid Leukemia (AML) Therapeutics Business (2017-2022)
    Figure 48. Roche Revenue Growth Rate in Acute Myeloid Leukemia (AML) Therapeutics Business (2017-2022)
    Figure 49. Genmab Revenue Growth Rate in Acute Myeloid Leukemia (AML) Therapeutics Business (2017-2022)
    Figure 50. GlaxoSmithKline Pharmaceuticals Revenue Growth Rate in Acute Myeloid Leukemia (AML) Therapeutics Business (2017-2022)
    Figure 51. Bottom-up and Top-down Approaches for This Report
    Figure 52. Data Triangulation
    Figure 53. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Bristol-Myers Squibb
Novartis
Roche
Genmab
GlaxoSmithKline Pharmaceuticals
Frequently Asked Questions
Acute Myeloid Leukemia (AML) Therapeutics report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Acute Myeloid Leukemia (AML) Therapeutics report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Acute Myeloid Leukemia (AML) Therapeutics report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports

Ad Insertion Servers

Ad Insertion Servers market is segmented by players, region (country), by Type and by Application ... Read More

Prenatal Screening

Prenatal Screening market is segmented by players, region (country), by Type and by Application.  ... Read More

Aged Care Services

Aged Care Services market is segmented by players, region (country), by Type and by Application.  ... Read More